Theralase Technologies Inc. V.TLT

RE:RE:RE:Keytruda

[investclub]

Well worth the repost


Hempdoc wrote

Quattro74 wrote:

This,

People don't mention enough that it is highly likely, certain even, that the 'optimized' process discovered in Phase 1s final two patients kicked off a strong immune response.

With only the one treatment... This is huge and that 2yr data is coming up, maybe they are waiting for this PR to coincide with more recent Phase 2 news.

harpos wrote: As I mentioned the other day, Merck expects to start at around 250 million a year now that they have been approved for NMIBC. Now per Bencro, they achieved a CR of 41 percent. So we only have to have CR in 2 of 5 patients to match that number. The data that we can possibly easily beat is durability of response.  Their median durability is 16 months. We already have two patients who have achieved 18 months and that is with one treatment. So, it would be huge if we get new data saying our patients went 24 months. It would also suggest we have achieved the immunity response that everyone seeks. Imagine that likely within 18 months we will either be getting the 250 million or we will have been bought out for billions. Again one treatment versus many, many treatments. Do you really have to ask what will drive our SP up in the short term as this story gets more and more exposure. 

Our ACT is certainly a two-headed snake...and based on our ACT's mechanism of action, there's the strong possibility the immune response/memory that's elicited after treatment will never have to be called into duty...in other words, our form of ACT could be that effective.  Again, targeted immunotherapy or an immune memory will generally keep cancer in check, but it's the targeted PDT that will keep it away, & possibly forever.  It doesn't discriminate.  Good luck...